R Santoyo V

Idioma: Español
Referencias bibliográficas: 27
Paginas: 28-34
Archivo PDF: 80.21 Kb.

FRAGMENTO

La aspirina que se utiliza con fines terapéuticos desde hace más de un siglo es, junto con los otros antiinflamatorios no esteroideos (AINE), de los medicamentos más prescritos en occidente y en varias partes del mundo en las últimas décadas. Tan sólo en los Estados Unidos se calcula que ›1% de la población los toma diariamente. En Australia, › 20% de la población de 65 años o más consume AINE cotidianamente.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fries JF. NSAID gastropahy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18 (Suppl. 28) : 6-10.

2. Coles LS, Fries JF, Kraines RG, Roth SH. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983; 74: 820-828.

3. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 23: 241-249.

4. Lichtenstein DR. Syngal S, Wolfe MM. Nonsteroidal Antiinflammatory Drugs And The Gastrointestinal Tract. The Double-Edged Sword. Arthritis Rheum 1995; 38: 5-18.

5. Roth SH, Bennett RE. Nonesteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med 1987; 147: 2093-2100.

6. Kraus A, Ibañez G. Antiinflamatorios no esteroideos. Una revisión práctica. Rev Invest Clín 1985; 37: 153-164.

7. Isakson PC, Verburg KM, Maziasz GS, Geis GD. Gastroenterol Intern 1999; 12: 169-177.

8. Graham DY, Smith JL. Aspirin and stomach. Ann Intern Med 1986; 104: 390-398.

9. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343: 769-772.

10. Cryer B, Feldman M. Effects of very low dose daily, longterm aspirin therapy on gastric, duodenal, and rectal prostaglandins levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25.

11. Pérez Gutthann S, García Rodríguez LA, Raidfor DS. Individual nonsteroidal anti-inflammatory drugs and hospitalizations for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18-24.

12. Geis GS, Stead H, Wallemarck CB, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis. An interim report of prevention by misoprostol of diclofenac associated lesions. J Rheumatol 1991; 18(Suppl 28): 11-4

13. 12a. Henry D, Lim, García Rodríguez LA et al. Variability in risk of gastrointestinal complication with individual nonsteroidal anti-inflammatory drugs: results of collaborative metaanalysis. BMJ 1996: 312: 1553-1566.

14. Asako H, Jubes P, Wallace J et al. Indometacin-induced leucocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol 1992; 262: G903-8.

15. 13a. Fiorucci S, Antonelli E, Santucci L et al. Gastrointestinal safety of nitric oxide-derived aspirin related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 1999; 116: 809.

16. 13b. Scarpignato C, Bjarnason I, Bretagne J-F, Pouvouruville G, García-Rodríguez LA, Goldstein JL, Muller P, Simon B. Towards a GI safer Antiinflammatory Therapy. Gastroenterology International 1999; 12: 186-215.

17. Márquez-Murillo MF, Suazo J, Poo JL. Gastropatía por antiinflamatorios no esteroides. Rev Invest Clín 1997; 49: 241-54.

18. 14a. Barrier CH, Hischowitz BI. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989; 32: 926-32.

19. 14b. Larkai EN Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989; 11: 158-162.

20. 14c. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32.

21. Avorn JV, Solomon D, Levin R et al. Epidemiology analysis of prophylactic drug use and NSAID gastropathy. Arthtrtis Rheum 1996; 39(Suppl) S185.

22. Dooley CP, Larson AW, Stace NH, Renner IG, Valenzuela JE et al. Double-contrast barium meal and upper gastrointestinal endoscopy: a comparative study. Ann Intern Med 1984; 101: 538-545.

23. Taha AS. Hystopathological aspects of mucosal injury related to non-steroidal anti-inflammatory drugs. Ital J Gastroenterol 1996; 28(Suppl 4): 12-15

24. Talley NJ. Healing of nonsteroidal anti-inflammatory drugassociated ulcers and erosions, and relief of dyspeptic symptoms: a commentary on the new data. Am J Med 1998; 104(3A) 62S-66S.

25. Yeomans ND, Tulassay Z, Juhasz L, Racz I. Howard JM, van Rensburg CJ et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl Med 1998; 338(11): 719-26.

26. Hawkey CJ, Karrasch JA Szczepanski L, Walker DG, Barkun A, Swannel AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 727-34.

27. Villanueva C, Balanzo J, Torras X, Sainz S, Soriano G, González D et al. Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study. Endoscopy 1995; 27: 308-312.